Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.07
PE(LYR):-285.00
PS:46.24

Loading ...

SKB BIO Receives Settlement Payment from Yilian Biopharma

Stock News
·
Jun 12

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives RMB602.5 Mln From Medilink Therapeutics for Out-Licensing of Yl201

THOMSON REUTERS
·
Jun 12

Movement Alert|Kelun-Biotech Falls 3.34% in Regular Trading, Biotech Sector Broadly Weakens Amid Ongoing Chairman Sell-Off Pressure

Market Focus
·
Jun 11

Hong Kong Stocks Show Movement: Super-Long-Acting Anti-TSLP Antibody Phase II Trial Completes First Dosing; HBM Holdings-B and SKB BIO Both Surge Over 5% During Session

Stock News
·
Jun 10

Movement Alert|Kelun-Biotech Rises 3.25% in Regular Trading, Multiple Brokerages Maintain Buy Ratings as ASCO Data Continues to Catalyze

Market Focus
·
Jun 10

Kelun-Biotech says partner Windward Bio doses first patients in Phase 2 COPD trial of SKB378/WIN378

Reuters
·
Jun 09

Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 Sirius Copd Study of Skb378/Win378

THOMSON REUTERS
·
Jun 09

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Simply Wall St.
·
Jun 08

Movement Alert|Kelun-Biotech Falls 3.15% in Regular Trading, Chairman Continuous Share Sales Combined with Widening Losses Sustain Selling Pressure

Market Focus
·
Jun 08

Domestic Innovative Drugs Initiate Paradigm Shift in First-Line NSCLC Treatment, Says Orient Securities

Stock News
·
Jun 08

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

Shares of SKB BIO Surge Over 7% on Milestone Breakthrough in OptiTROP-Lung05 Study

Stock News
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.54% in Regular Trading, Buyback Plan and ASCO Clinical Data Provide Dual Catalysts

Market Focus
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.08% at Open, Proposed Buyback of Up to 10% H Shares Boosts Sentiment

Market Focus
·
Jun 05

SKB BIO Announces Investment in Structured Deposit Product

Stock News
·
Jun 03

Sichuan Kelun-Biotech Biopharmaceutical Co - Subscribes for Czb Structured Deposit Iii of RMB190 Mln on April 22, 2026

THOMSON REUTERS
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.17% in Regular Trading, Performance Slowdown and Chairman Stake Reduction Continue to Pressure Shares

Market Focus
·
Jun 03

Kelun-Biotech says SKB500 posts 42.7% response rate in first-in-human solid tumor study at ASCO 2026

Reuters
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 6.11% in Regular Trading, Chairman Consecutive Share Sales Compound Performance Concerns

Market Focus
·
Jun 02

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing

Market Focus
·
Jun 01